Evoncabtagene pazurgedleucel

N/A

Report date: 2025/01/09 20:00:05

Base Information

Drug NameEvoncabtagene pazurgedleucel

Drug Alias NameCD19-directed T-cell immunotherapy (CRISPR Therapeutics)CTX-110

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV6 vector +[4]

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesAustralia +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCrispr Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCrispr Therapeutics Ag

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4]

Other Information

ATC CodeN/A